Benefits of neoadjuvant therapy compared with adjuvant chemotherapy for the survival of patients with HER2-positive breast cancer: A retrospective cohort study at FUSCC

Zheng, Shuyue; Li, Lun; Chen, Ming; Yang, Benlong; Chen, Jiajian; Li, Guangyu; Shao, Zhimin; Wu, Jiong

doi:10.1016/j.breast.2022.03.015

Cited by 6 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, the expression of HER2 is significantly correlated with tumor response, which is in agreement with the subjects and results of a retrospective study by Zheng et al. They confirmed that the response of adjuvant therapy is equivalent to that of NAT in patients with HER2+ and emphasized that patients with cT3/4 or those with positive clinical nodal status were more likely to benefit from NAT ( 25 ). Because of the overexpression of the oncogene ERBB2, HER2+ promotes the growth of cancer cells, which results in positive progress and a worse prognosis ( 26 ).…”

Section: Discussionsupporting

confidence: 92%

Prediction of clinical response to neoadjuvant therapy in advanced breast cancer by baseline B-mode ultrasound, shear-wave elastography, and pathological information

et al. 2023

View full text Add to dashboard Cite

BackgroundNeoadjuvant therapy (NAT) is the preferred treatment for advanced breast cancer nowadays. The early prediction of its responses is important for personalized treatment. This study aimed at using baseline shear wave elastography (SWE) ultrasound combined with clinical and pathological information to predict the clinical response to therapy in advanced breast cancer.MethodsThis retrospective study included 217 patients with advanced breast cancer who were treated in West China Hospital of Sichuan University from April 2020 to June 2022. The features of ultrasonic images were collected according to the Breast imaging reporting and data system (BI-RADS), and the stiffness value was measured at the same time. The changes were measured according to the Response evaluation criteria in solid tumors (RECIST1.1) by MRI and clinical situation. The relevant indicators of clinical response were obtained through univariate analysis and incorporated into a logistic regression analysis to establish the prediction model. The receiver operating characteristic (ROC) curve was used to evaluate the performance of the prediction models.ResultsAll patients were divided into a test set and a validation set in a 7:3 ratio. A total of 152 patients in the test set, with 41 patients (27.00%) in the non-responders group and 111 patients (73.00%) in the responders group, were finally included in this study. Among all unitary and combined mode models, the Pathology + B-mode + SWE model performed best, with the highest AUC of 0.808 (accuracy 72.37%, sensitivity 68.47%, specificity 82.93%, P<0.001). HER2+, Skin invasion, Post mammary space invasion, Myometrial invasion and Emax were the factors with a significant predictive value (P<0.05). 65 patients were used as an external validation set. There was no statistical difference in ROC between the test set and the validation set (P>0.05).ConclusionAs the non-invasive imaging biomarkers, baseline SWE ultrasound combined with clinical and pathological information can be used to predict the clinical response to therapy in advanced breast cancer.

show abstract

Section: Discussionsupporting

confidence: 92%